Vaxcyte, Inc. (PCVX) Covered Calls
Vaxcyte, Inc. is a clinical-stage vaccine innovation company developing high-fidelity vaccines to prevent serious bacterial diseases. The company’s proprietary XpressCF cell-free protein synthesis platform allows for the design of broad-spectrum conjugate vaccines with enhanced immunogenicity. Its lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) aiming to set a new standard in protection against invasive pneumococcal disease for both adults and infants.
You can sell covered calls on Vaxcyte, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PCVX (prices last updated Tue 4:16 PM ET):
| Vaxcyte, Inc. (PCVX) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 58.24 | -1.08 | 43.00 | 64.86 | 748K | - | 7.8 |
| Covered Calls For Vaxcyte, Inc. (PCVX) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 60 | 1.30 | 63.56 | -5.6% | -185.8% | |
| Apr 17 | 60 | 2.20 | 62.66 | -4.2% | -39.3% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Vaxcyte is a biotechnology firm dedicated to re-engineering the way complex vaccines are manufactured. The company’s core technology is the XpressCF platform, a cell-free protein synthesis system licensed from Sutro Biopharma. This platform enables Vaxcyte to bypass the limitations of traditional cell-based manufacturing, allowing for the precise, site-specific conjugation of a higher number of antigens without sacrificing the vaccine’s overall immune response. This "carrier-sparing" approach is the foundation of their lead product candidate, VAX-31.
VAX-31 is a 31-valent pneumococcal conjugate vaccine designed to cover approximately 95% of the serotypes causing invasive pneumococcal disease (IPD) in U.S. adults. By early 2026, Vaxcyte has advanced VAX-31 into a pivotal Phase 3 program, including the OPUS-1 non-inferiority trial. The pipeline also includes VAX-24, a 24-valent candidate, and earlier-stage programs targeting Group A Strep (VAX-A1), Shigella (VAX-GI), and periodontal disease (VAX-PG). The company is currently building out dedicated commercial-scale manufacturing lines in partnership with Lonza and Thermo Fisher Scientific to support its future product launches.
Competitive Landscape
The vaccine market is dominated by a few massive pharmaceutical entities with established distribution networks. Vaxcyte’s primary competition comes from incumbents in the pneumococcal space, specifically Pfizer (with Prevnar 20) and Merck (with Capvaxive). Within the biotechnology and pharmaceutical sectors, primary competitors listed on the NYSE or NASDAQ with active, liquid options chains include Pfizer Inc., Merck & Co., GSK plc, and BioNTech SE. Additionally, the company is often compared to other high-growth biotech innovators like Moderna, which are also exploring next-generation vaccine platforms.
Strategic Outlook and Innovation
Vaxcyte’s strategy for 2026 is centered on completing the pivotal data readouts for VAX-31 to support a planned Biologics License Application (BLA) submission by 2027. A key area of innovation is the company’s "site-specific conjugation" technique, which ensures that each antigen is attached to the carrier protein in a way that maximizes the visibility of the pathogen to the human immune system. This technology is expected to give Vaxcyte a "best-in-class" profile, potentially outperforming existing vaccines that rely on more random, less efficient conjugation methods.
Strategically, the company is shifting from a purely R&D-focused organization to one ready for commercial scale. This involves the completion of its custom fill-finish manufacturing lines in North Carolina, which will provide the infrastructure necessary for a global rollout. Vaxcyte also intends to initiate pediatric Phase 3 trials for VAX-31 in 2026, following positive Phase 2 results in infants. With a multi-billion dollar cash runway, the firm is well-positioned to fund its clinical milestones and navigate the regulatory approval process without the immediate need for dilutive financing. The long-term goal is to replace the current standard-of-care with a more comprehensive, higher-valency solution that addresses the evolving landscape of bacterial resistance.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | FXI covered calls | 3. | USO covered calls | |
| 4. | SPY covered calls | 9. | GLD covered calls | 4. | FLY covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | ONDS covered calls | |
Want more examples? PCTY Covered Calls | PCY Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
